246 results about "Adema disease" patented technology

This invention is directed to methods for identifying apoptosis signal-regulated kinase 1 (“ASK1”) inhibitors useful for preventing and/or treating cardiovascular disease. This invention also relates to methods for preventing and/or treating cardiovascular disease in an animal by administering to the animal an ASK1 inhibitor.

The invention belongs to the field of allogenic mesenchymal stem cells, and particularly relates to a preparation method of allogenic mesenchymal stem cells by CRISPR (clustered regularly interspaced short palindromic repeats) technique editing and IGF (insulin-like growth factor) optimization and application of the allogenic mesenchymal stem cells in treating myocardial infarction. The preparation method comprises the following steps: carrying out separation by density gradient centrifugation to obtain allogenic single karyocytes, and carrying out adherent culture to obtain mesenchymal stem cells; designing a mesenchymal stem cell surface antigen B2M-gRNA and an inflammatory factor TNF-alpha-gRNA; establishing recombinant slow virus particles, and transfecting the mesenchymal stem cells; optimizing the mesenchymal stem cells by using IGF-1; and preparing drugs for treating myocardial infarctions by using the modified and optimized mesenchymal stem cells. The CRISPR/Cas9 technique is utilized to remove the antigens capable of causing immunological rejection and the inflammatory factors capable of causing inflammatory reaction on the mesenchymal stem cell surface, and the IGF-1 is utilized to enhance the apoptosis resistance of the mesenchymal stem cells and promote the homing of the mesenchymal stem cells, thereby providing a new technical scheme for preparing drugs for treating cardiovascular diseases in clinic. The prepared allogenic mesenchymal stem cells can not cause immunological rejection after cell transplantation.

The invention related to methods of treating disease related to vasoconstriction that is a major factor in hypertensive vascular diseases and vasodilation, generally comprising administering to an individual an effective amount of a pharmaceutically active relaxin. Relaxin functions to increase both vasodilation and angiogenesis in males as well as females, and is useful in treating a wide variety of diseases relating to vasoconstriction.

The invention discloses a pharmaceutical composition for treating hypertension and other cardiovascular diseases, wherein the active constituents include pharmaceutical salts of levamlodipine besylate and angiotensin II receptor antagonists. The invention can not only overcome the drawback of photodecomposition of the levoamlodipine maleate medicaments, but also can increase the dissolving degree by 21%.

Disclosed are methods of identifying subjects with arteriovascular disease, subjects at risk for developing arteriovascular disease, methods of differentially diagnosing diseases associated with arteriovascular disease from other diseases or within sub-classifications of arteriovascular disease, methods of evaluating the risk of arteriovascular events in patients with arteriovascular disease, methods of evaluating the effectiveness of treatments in subjects with arteriovascular disease, and methods of selecting therapies for treating arteriovascular disease.

Methods and apparatus are disclosed for the measurement of lipocalin-2 in body fluids (including but not limited to blood, serum, plasma, urine, saliva, tear, etc.) by an assay such as an immunoassay or an immunotest for (1) the prediction of risk of future cardiovascular diseases; and (2) the determination of the likelihood that certain individuals will benefit to a greater or lesser extent from the use of certain treatments designed to prevent and/or treat cardiovascular diseases.

The present invention provides methods of expressing a nucleic acid or producing a proteinaceous composition encoded by a nucleic acid in vascular and cardiovascular cells by administration of a herpesvirus vector. The present invention provides methods of producing a therapeutic benefit in vascular and cardiovascular tissue by administration of a herpesvirus vector. In additional aspects, the invention concerns combination therapies for vascular and cardiovascular diseases comprising administration of a herpesvirus vector and treatment with at least one addition pharmacological agent or surgical procedure.

A method is provided for reducing the treatment burden for patients who have an intraocular neovascular disorder, the method comprising administering a therapeutically effective amount of VEGF antagonist on a dosing schedule that includes treatment intervals of 8 and/or 12 weeks.

The invention relates to pharmacology and medicine, in particular to a class of mitochondrially-addressed compounds which can be used in the pharmaceutical compositions of medicinal agents (preparations) for preventing and treating cardiovascular diseases and diseases and pathological conditions caused by disturbed blood circulation or oxygen supply to tissues and organs.

The invention discloses a large data cardiovascular disease risk monitoring system. According to the system, personal information (including age, sex, blood pressure, height, weight, obesity index and the like) of health examinations, physical examinations and hospital treatment, and test data of blood routine, blood biochemistry and myocardial enzymes are used for monitoring the cardiovascular disease risk. The invention belongs to the application of large data in the field of health care, and further belongs to the crossing technical field of large data and health care. The invention aims at providing a simple, easy, practical and accurate cardiovascular risk monitoring system. The current monitoring of the cardiovascular disease risk is achieved mostly by enquiring a small sample amount of data collected by a questionnaire method such as disease history, family history and major risk factors for the cardiovascular disease and through the data of blood sugar collected by an instrument, total cholesterol and the like. The monitoring is controlled and managed by medical institutions and doctors so that users can not carry out the monitoring of the cardiovascular disease risk by themselves. Due to the fact that epidemiological features of a cardiovascular disease spectrum and risk factors in Chinese population are significantly different from the epidemiological features in western developed countries. The existing risk assessment tools in Europe and America are not suitable for the Chinese population. With the help of a large data value extraction technology, the large data cardiovascular disease risk monitoring system can monitor the cardiovascular disease risk for users and doctors and provide hope for human to monitor the cardiovascular disease risk by themselves and conquer the cardiovascular disease.

Provided herein are methods and systems for the treatment of cardiovascular conditions, including pulmonary hypertension (PH), in subjects that are being treated with a treatment regimen that includes a phosphodiesterase-5 (PDE-5) inhibitor.

The invention belongs to the technical field of gene detection, and relates to a reagent kit for detecting cardiovascular disease medication genes and a detection method. The reagent kit comprises a detection reagent for 17 mutant sites of 11 genes, in accordance with exceptional gene variation sites of the 11 genes, an amplification primer and a single-basic-group extension primer of each site are designed, through multiplex PCR and a multiple single-basic-group extension reaction, mass spectrometric analysis is performed on a specific product, and the genotype of each site is judged. The detection specificity is high, the sensitivity is high, and the reagent kit can be applied to scientific research, medicine treatment effect research, cardiovascular disease relevant investigation and cardiovascular system clinical medication guidance.

The present invention relates to a medicine for curing cerebrovascular diseases and its preparation method. The effective component of said medicine is gardenia total iridoid glycoide extracted from Chinese medicinal material gardenia root, in which its main component is gardenaside. Said invention also provides dosage form of said medicine, specially provides its capsule preparation.

Embodiments of the present invention include methods for the treatment, prevention, or amelioration of vascular disease in diabetic patients. The methods include both implantation of a stent including a first drug. Some embodiments include additional therapy, such as the co-administration of another drug. Some embodiments involve different stent selection for a diabetic patient compared to a non-diabetic patient.

The invention discloses a DNA library for detecting pathogenic genes of multiple genetic vascular diseases through a targeted high-throughput semiconductor sequencing technology and application thereof. The operating method specifically comprises the following steps: designing a primer pool according to 151 pathogenic genes of genetic vascular diseases, performing super-multiple PCR amplification on genomic DNA of samples, sequencing the amplification products by utilizing the high-throughput semiconductor sequencing technology, searching pathogenic mutations, and providing genetic and molecular biological theoretical basis for clinical diagnosis. The DNA library disclosed by the invention has the characteristics of accuracy, rapidness, flexibility and low cost, the 151 gene detection areas involved in the invention are capable of detecting multiple genetic vascular diseases such as aortic dissection, arterial aneurysm, hemorrhagic apoplexy and the like, and the DNA library has great significance and clinical values on diagnosis and differential diagnosis of the genetic vascular diseases.

The invention discloses a traditional Chinese medicinal composition for treating cardiovascular diseases and belongs to the field of traditional Chinese medicaments. The traditional Chinese medicinal composition is prepared by the following steps of: extracting active ingredients from raw material medicaments, such as pericarpium trichosanthis, longstamen onion bulb, szechuan lovage rhizome and the like, by adopting the methods of different-concentration ethanol extraction, water extraction and the like respectively according to different properties of the medicaments; and preparing dropping pills, soft capsules, capsules, tablets and pills. The traditional Chinese medicinal composition is clinically used for treating diseases such as a coronary heart disease, angina pectoris, hyperlipidaemia, atherosclerosis and the like. The invention also discloses a preparation method of the traditional Chinese medicinal composition.

The invention belongs to the field of life science, relates to an application of a probiotic preparation in treating and preventing vascular dementia, in particular to a new application of medicine for preventing and treating vascular dementia through clostridium butyricum. Vascular dementia is brain tissue damage existing on the basis of multiple cerebrovascular diseases and the syndrome with cognition impairment as main clinical manifestation. The probiotic preparation for preventing and treating vascular dementia comprises medicine, healthcare products and drinks. No toxic or side effect is found. Intestinal flora is creatively adopted as treatment target points, a new pattern for preventing and treating vascular dementia is created, disease symptoms are relieved, nerve cell damage is retarded, good social and economic benefits are achieved, and the probiotic preparation is worthy of being applied and popularized.

The present invention relates to a hemorrhage reducing agent in cerebrovascular disorder containing a poly (ADP-ribose) polymerase inhibitor (PARP inhibitor). The PARP inhibitor provides an inhibitory effect of vascular endothelial cell disorder so that it may reduce hemorrhage in cerebrovascular disorder. In addition, the PARP inhibitor inhibits the hemorrhage that is concerned about in thrombolytic agent use by using together with a thrombolytic agent, and an effect of extending therapeutic time window of a thrombolytic agent may be further expected. Furthermore, the PARP inhibitor can be a safe hemorrhage reducing agent with fewer side effects because it does not affect the blood coagulation system and the fibrinolytic system.

The present invention relates generally to the field of therapy. The invention particularly relates to insulin sensitisers and methods of regulating glucose homeostasis and to the therapeutic or prophylactic treatment of diseases and associated conditions, in which impaired glucose uptake due to insulin resistance is involved or implicated, such as diabetes, syndrome X, hyperglycaemia, vascular disease and kidney disease. The present invention further relates to compounds and agents and compositions thereof for use in the treatment methods.